Market Cap
$52.0M
IMA
ImageneBio, Inc.
$4.60 ▲ +0.44%
Prev close $4.58Market cap$52.0M
ConsensusBuy
12-mo target$18.00 (+291.3%)
▲ Bullish
Analyst conviction 8/10
Biotech & Drug Discovery
Snapshot
The big-picture read on IMA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (75%)
Inst. Holders
19 funds
Inst. Value
$7.1M
Inst. Activity
2 buys / 2 sells
Insider Activity
$0.00 buy / $17.3K sell
Insider Net $
-$17.3K
SEC Reports
5
Press Releases
3
Price chart 30d -5.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Compa
Aug 14, 2026 Insider
Yarema Kristin was granted 137,200 shares
Chief Executive Officer
Aug 14, 2026 Insider
Yarema Kristin was granted 254,800 shares
Chief Executive Officer
Aug 14, 2026 Insider
Aug 7, 2026 SEC Yarema Kristin was granted 250,000 shares
Chief Executive Officer
ImageneBio's registration statement (File No. 333-290108) became effective on August 6, 2026, under the Securities Act o
EFFECT — Impact 5/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — TRIM
55,610 shares ($328.1K)
Jun 30, 2026 Inst.
Jun 26, 2026 SEC GOLDMAN SACHS GROUP INC — ADD
15,485 shares ($91.4K)
ImageneBio disclosed the resignation of Robert Lally, SVP of Finance and Operations and principal accounting officer, ef
8-K — Impact 3/10
Analyst ratings buy % +5.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
75% rate it Buy or better · 8 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 21, 2026 | HC Wainwright & Co. | INITIATE | Buy | 43% |
| May 11, 2026 | Wedbush | REITERATE | Underperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 3 | 1 | 0 | 1 | 75% | |
| Aug 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| Jul 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| Jun 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| May 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| Apr 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| Mar 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% | |
| Feb 1, 2026 | 3 | 2 | 1 | 0 | 1 | 71% |
Price targets
Where 3 covering analysts think IMA trades over the next 12 months.
$18.00 +291.3% upside Strong Buy
Current$4.60 Low$2.00 Median$24.00 High$28.00 3 analysts
$2.00$28.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 3 neutral · avg impact 4.0/10.Plus 3 press releases.
BEARISHEFFECT5/10
ImageneBio's registration statement (File No. 333-290108) became effective on August 6, 2026, under
Aug 7, 2026
NEUTRAL8-K3/10
ImageneBio disclosed the resignation of Robert Lally, SVP of Finance and Operations and principal ac
Jun 26, 2026
NEUTRALDEFA14A3/10
ImageneBio filed a DEFA14A (definitive additional proxy soliciting materials) on April 30, 2026. The
Apr 30, 2026
BEARISH8-K6/10
ImageneBio is raising $30 million through a private placement of pre-funded warrants, which allows i
Apr 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, t
Sep 8, 2026
other
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer
Aug 5, 2026
earnings
ImageneBio Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quar
Jul 22, 2026
earnings_calendar
IMA Q2 2026 Earnings After Market Close — 2026-07-22
Jul 7, 2026
other
ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.85 | $-0.98–$-0.72 | 70.9% | +31.4% | 2↑ 0↓ | $0.0B | 3 |
| Next Q | $-0.97 | $-1.02–$-0.91 | — | +26.2% | 2↑ 0↓ | $0.0B | 3 |
| Current FY | $-3.31 | $-3.57–$-3.18 | 65.7% | +26.1% | 2↑ 0↓ | $0.0B | 3 |
| Next FY | $-4.31 | $-5.48–$-2.99 | -30.2% | -8.3% | 1↑ 1↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.847 | — |
| 7d ago | $-0.780 | -0.067 |
| 30d ago | $-1.235 | +0.388 |
| 60d ago | $-1.235 | +0.388 |
| 90d ago | $-1.235 | +0.388 |
Institutional ownership
Which big funds own IMA (from quarterly 13F filings) and who is adding or trimming.
19 institutional holders with $7.1M total value (1,196,340 shares) as of 2026-Q2. Top holders: RTW, VANGUARD, BlackRock,.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 334,445 | $2.0M | 27.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 320,518 | $1.9M | 26.8% | — |
| BlackRock, Inc. | 135,090 | $797.0K | 11.3% | DOUBLED +152.5% |
| RENAISSANCE TECHNOLOGIES LLC | 86,930 | $512.9K | 7.3% | ADD +76.8% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 66,666 | $393.3K | 5.6% | — |
| CITADEL ADVISORS LLC | 55,610 | $328.1K | 4.6% | TRIM -55.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 53,512 | $315.8K | 4.5% | — |
| HSBC HOLDINGS PLC | 34,228 | $208.4K | 3.0% | — |
| VANGUARD FIDUCIARY TRUST CO | 27,475 | $162.1K | 2.3% | — |
| TWO SIGMA INVESTMENTS, LP | 19,900 | $117.4K | 1.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | TRIM | 124,345 | 55,610 | -55.3% | $328.1K |
| GOLDMAN SACHS GROUP INC | ADD | 11,458 | 15,485 | +35.1% | $91.4K |
| UBS Group AG | ADD | 5,428 | 6,879 | +26.7% | $40.6K |
| JPMORGAN CHASE & CO | NEAR_EXIT | 293 | 70 | -76.1% | $425.00 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | 18,727 | 26,663 | +42.4% | $133.3K |
| MORGAN STANLEY | ADD | 10,771 | 18,339 | +70.3% | $91.7K |
| JPMORGAN CHASE & CO | DOUBLED | 70 | 293 | +318.6% | $1.5K |
| NewEdge Advisors, LLC | TRIM | 491 | 160 | -67.4% | $800.00 |
| BlackRock, Inc. | DOUBLED | 52,111 | 131,587 | +152.5% | $908.0K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 37,378 | 66,096 | +76.8% | $456.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 21 transactions. Net -$17.3K — $0.00 bought, $17.3K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Yarema Kristin | Chief Executive Officer | AWARD | 137,200 | — | — |
| Aug 14, 2026 | Yarema Kristin | Chief Executive Officer | AWARD | 254,800 | — | — |
| Aug 14, 2026 | Yarema Kristin | Chief Executive Officer | AWARD | 250,000 | — | — |
| Aug 14, 2026 | Grant-Huerta Yanina | Chief Financial Officer | AWARD | 65,000 | — | — |
| Aug 14, 2026 | Grant-Huerta Yanina | Chief Financial Officer | AWARD | 39,000 | — | — |
| Aug 14, 2026 | Grant-Huerta Yanina | Chief Financial Officer | AWARD | 56,000 | — | — |
| Jul 25, 2026 | Yarema Kristin | Chief Executive Officer | EXERCISE | 38,376 | — | — |
| Jul 25, 2026 | Yarema Kristin | Chief Executive Officer | J | 115,129 | — | — |
| Jul 25, 2026 | Yarema Kristin | Chief Executive Officer | J | 115,129 | — | — |
| Jul 17, 2026 | Lally Robert B | Principal Accounting Officer | SELL | 1,525 | $5.34 | $8.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IMA.
Shares short
34,601
Settlement Sep 15, 2026
Change vs prior
-12.2%
Semi-monthly cycle
Days to cover
2.3
At avg daily volume
Of shares outstanding
≈0.3%
Estimate — not % of float
All IMA filing & press-release reports (8)
- EFFECT reportAug 7, 2026
- 8-K reportJun 26, 2026
- DEFA14A reportApr 30, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- EFFECT reportApr 6, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026